Clinical Trial Update: Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is evaluating whether adding tislelizumab with apatinib and oxaliplatin plus S-1 as neoadjuvant therapy improves outcomes in patients with adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Immunotherapy Gastrict Cancer | Phase 2, Phase 3 | Status: RECRUITING